ClinicalTrials.gg
CompletedNCT00315705Updated Apr 14, 2014Results posted

A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias.

A Phase 1/2 interventional study of clofarabine and Etoposide in Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia and Relapsed Leukemia, sponsored by Genzyme, a Sanofi Company. Completed at 13 sites in United States. Open to participants aged 1 Year to 21 Years. Per ClinicalTrials.gov, last updated 2014-04-14.

Sponsored by Genzyme, a Sanofi Company (part of Sanofi) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
1 Year to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 55 studies testing clofarabine in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 3 open to participants now, 4 under way, 1 of them phase 3. Clofarabine · Precursor Cell Lymphoblastic Leukemia-Lymphoma.

Enrollment
18th of 54
50 · median 35
Started
2006
with 4 others
Phase 1/2
10 of 55
none open now
Registered
6th of 55
by date
Lead sponsor
6 of 55
Genzyme, a Sanofi Company

Among the 55 studies testing clofarabine in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 18th largest by enrollment of the 54 interventional ones that give a count, is one of 5 that started in 2006, is one of 10 in phase 1/2, and was the 6th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,585 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 473 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

3 of the 55 studies testing clofarabine in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About clofarabine

Clofarabine: first FDA approval 2004 (CLOLAR), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 370 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (69%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 1 Year to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing clofarabine in Precursor Cell Lymphoblastic Leukemia-Lymphoma, or all of them as a file.
02

Study summary

Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia (ALL) who have had at least 2 prior treatment regimens. This use is based on the induction of complete responses. Randomized trials demonstrating increased survival or other clinical benefit have not been conducted.

The purpose of the phase 1 portion of this study was to determine if clofarabine added to a combination of etoposide and cyclophosphamide is safe in children with relapsed or refractory acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML). The purpose of the phase 2 portion of the study was to measure the effectiveness of the combination therapy in children with ALL.

03

Conditions studied

  • Acute Lymphoblastic Leukemia
  • Acute Myelogenous Leukemia
  • Relapsed Leukemia

Keywords

  • clofarabine
  • acute leukemia
  • ALL
  • AML
  • clolar
  • CLO218
04

Who can participate

Ages eligible
1 Year to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • NOTE: the following eligibility criteria were applicable to acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML) patients for the Phase 1 portion of this study, and to ALL patients for the Phase 2 portion of the study (only ALL patients were allowed in the Phase 2 portion of the study).
  • ALL with > 25% blasts in bone marrow; AML with ≥ 5% blasts in bone marrow; ALL and AML patients may have extramedullary disease
  • Performance Status ≥ 50 for patients > 10 years old; Lansky Performance Status ≥ 50 for patients ≤ 10 years old
  • Prior therapy: AML: 1-2 prior induction regimens and ≤ 1 hematopoietic stem cell transplant (); ALL: 1-3 prior induction regimens
  • Adequate liver, renal, pancreatic, and cardiac function
  • Have received no prior HSCT (study amended in Phase 2 to exclude patients with prior HSCT)

Exclusion criteria

Exclusion Criteria:

  • NOTE: the following eligibility criteria were applicable to ALL and AML patients for the Phase 1 portion of this study, and to ALL patients for the Phase 2 portion of the study (only ALL patients were allowed in the Phase 2 portion of the study).
  • Burkitt's leukemia
  • Previous treatment with clofarabine
  • Uncontrolled systemic fungal, bacterial or other infection and 48 hrs negative blood cultures required for patients with a history of fever within 3 days of enrollment
  • Active CNS involvement (i.e., should be CNS1 or CNS2)
  • Inadequate time since last therapy: ≤ 14 days since last cytotoxic chemotherapy; ≤ 7 days since last biologic therapy; ≤ 14 days since last monoclonal antibody therapy
  • Have received prior (study amended in Phase 2 to exclude patients with prior HSCT)
  • Pregnant or lactating
  • Have tested positive for or infection or history of cirrhosis
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    clofarabine, etoposide, cyclophosphamide

    Phase 1: escalating dosage of the three drugs delivered intravenously. Clofarabine dosage from 20-40 mg/m\^2, etoposide dosage from 75-100 mg/m\^2, cyclophosphamide dosage from 340-440 mg/m\^2. Phase 2: The recommended phase 2 doses (RP2D) were clofarabine 40 mg/m\^2, etoposide 100 mg/m\^2 and cyclophosphamide 440 mg/m\^2 delivered intravenously

    Drug: clofarabine · Drug: Etoposide · Drug: Cyclophosphamide

Interventions

  • Clofarabine 20-40 mg/m²/day 2 hour intravenous (IV) infusion daily for 5 days of a 28 day cycle as the first of the three IV interventions administered. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.

    Also known as: Clolar, Evoltra

  • Etoposide 75-100 mg/m²/day 2 hour intravenous (IV) infusion daily for 5 days of a 28 day cycle following clofarabine therapy. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.

    Also known as: Eposin

  • Cyclophosphamide 340-440 mg/m²/day as 30-60 minute intravenous (IV) infusion daily for 5 days of a 28 day cycle following the other two interventions. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.

    Also known as: Endoxan, Revimmune, Cytoxan

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD) in Phase 1

    The MTD was to be the highest dose level of clofarabine in combination with etoposide and cyclophosphamide that caused \<= 1 of 6 participants to experience a dose limiting toxicity (DLT) with the next higher dose level having at least 2 of 3 or 2 of 6 participants experiencing a DLT. The MTD would be used as the recommended phase 2 dose (RP2D). If the MTD could not be determined, then the target dose of clofarabine 40 mg/m\^2, etoposide 100 mg/m\^2 and cyclophosphamide 440 mg/m\^2 as taken by Cohort 5 was to become the RP2D. The rating scale used is 0 = not the MTD, 1 = the MTD.

    Time frame: Up to Day 42 (Phase 1 portion of study)

  2. Participants With Dose Limiting Toxicity in Phase 1

    The number of participants in each cohort that had dose limiting toxicity is summarized. Toxicities were reviewed by an independent Data Safety Monitoring Board (DSMB) who determined if additional participants should be added to the cohort and the criteria for escalating to the next cohort.

    Time frame: Up to Day 42 (Phase 1 portion of study)

  3. Percentage of Participants Achieving A Response Over the First Two Treatment Cycles in Phase 2

    Response categories 1) complete remission (CR): without circulating blasts or extramedullary disease, bone marrow (BM) with \<5% blasts, and platelet (plt)/ANC recovery: ≥75/ ≥0.75 \[x 10\^9/L\] 2) CR in absence of plt recovery (CRp): plt ≥20 to \<75 x 10\^9/L 3) partial remission (PR): no circulating blasts, appearance of normal hematopoietic progenitors, and either a BM with ≥5% and ≤25% blasts with recovery of plts/ANC or a BM with \<5% blasts not meeting CR/CRp definition 4) Overall remission (OR): CR+CRp 5) Any response: CR+CRp+PR.

    Time frame: Approximately 28-56 days (Phase 2 portion of study)

Secondary outcomes

  1. Summary of Participants With Adverse Events (AEs) in Phase 1

    Number of participants with AEs that occurred during treatment and follow-up period (45 days after last cycle). Drug-related AEs and SAEs were followed until resolved or mutually agreed by the investigator and Genzyme to discontinue reporting. AEs were classified by the investigator according to severity (graded using National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE\] version 3.0) and relationship to study drug. The severity scale is:\> Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening or disabling, Grade 5=Death related to AE

    Time frame: Up to 9.5 months (Phase 1 portion of study)

  2. Percentage of Participants Achieving A Response Over the First Two Treatment Cycles in Phase 1

    Response categories 1) complete remission (CR): without circulating blasts or extramedullary disease, bone marrow (BM) with \<5% blasts, and platelet (plt)/ANC recovery: ALL ≥75/ ≥0.75 \[x 10\^9/L\]; AML ≥100/ ≥1.0 \[x 10\^9/L\] 2) CR in absence of plt recovery (CRp): ALL plt ≥20 to \<75 x 10\^9/L; AML plt ≥20 to \<100 x 10\^9/L 3) partial remission (PR): no circulating blasts, appearance of normal hematopoietic progenitors, and either a BM with ≥5% and ≤25% blasts with recovery of plts/ANC or a BM with \<5% blasts not meeting CR/CRp definition 4) Overall remission (OR): CR+CRp 5) Any response: CR+CRp+PR.

    Time frame: Approximately 2 months (Phase 1 portion of study)

  3. Time to Remission for Participants Who Had a Response in Phase 1

    The weeks between start of intervention and remission as assessed by the investigator in Phase 1. Participants who had a complete remission (CR) or complete remission with the absence of total platelet recovery (CRp) are included.

    Time frame: up to 8 weeks (Phase 1 portion of study)

  4. Kaplan Meier Estimate of Duration of Remission (DOR) for Participants Who Achieved Overall Remission (OR) in Phase 1

    Duration of response is the time from the first objective measurement of complete response (CR) or complete response with the absence of total platelet recovery (CRp) to the date of first objective documentation of disease relapse or death due to any cause, plus one day. For summary purposes, results are presented as weeks.

    Time frame: Up to 2 years (Phase 1 portion of study)

  5. Kaplan Meier Estimates of Event-free Survival (EFS) for Participants in Phase 1

    Event-free survival (EFS) is defined as the time from date of first administration of study interventions until the earliest of the following: date of death or date of first response assessment confirming relapse or date of final response assessment which fails to confirm response, plus one day. For summary purposes, results are presented as weeks.

    Time frame: Up to 2 years (Phase 1 portion of study)

  6. Number of Participants With 4-month Event Free Survival in Phase 1

    Number of participants with event-free survival at four months post first dose of therapy. A participant is considered event-free if at month 4 they have not died or had a response assessment confirming a relapse.

    Time frame: 4 months (Phase I portion of study)

  7. Kaplan Meier Estimates of Overall Survival (OS) for Participants in Phase 1

    Overall survival is defined as the time from date of first administration of study interventions until date of death, plus one day. For summary purposes, results are presented as weeks.

    Time frame: Up to 2 years (Phase 1 portion of study)

  8. Summary of Participants With Adverse Events (AEs) in Phase 2

    Number of participants with AEs that occurred during treatment and follow-up period (45 days after last cycle). Drug-related AEs and SAEs were followed until resolved or mutually agreed by the investigator and Genzyme to discontinue reporting. AEs were classified by the investigator according to severity (graded using National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE\] version 3.0) and relationship to study drug. The severity scale is:\> Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening or disabling, Grade 5=Death related to AE

    Time frame: Up to 9.5 months (Phase 2 portion of study)

  9. Time to Remission for Participants Who Had a Response in Phase 2

    The weeks between start of intervention and remission as assessed by the investigator in Phase 2. Participants who had a complete remission (CR) or complete remission with the absence of total platelet recovery (CRp) are included.

    Time frame: up to 8 weeks (Phase 2 portion of study)

  10. Kaplan Meier Estimate of Duration of Remission (DOR) for Participants Who Achieved Overall Remission (OR) in Phase 2

    Duration of response is the time from the first objective measurement of complete response (CR) or complete response with the absence of total platelet recovery (CRp) to the date of first objective documentation of disease relapse or death due to any cause, plus one day. For summary purposes, results are presented as weeks.

    Time frame: Up to 2 years (Phase 2 portion of study)

  11. Kaplan Meier Estimates of Event-free Survival (EFS) for Participants in Phase 2

    Event-free survival (EFS) is defined as the time from date of first administration of study interventions until the earliest of the following: date of death or date of first response assessment confirming relapse or date of final response assessment which fails to confirm response, plus one day. For summary purposes, results are presented as weeks.

    Time frame: Up to 2 years (Phase 2 portion of study)

  12. Number of Participants With 4-month Event Free Survival in Phase 2

    Number of participants with event-free survival at four months post first dose of therapy. A participant is considered event-free if at month 4 they have not died or had a response assessment confirming a relapse.

    Time frame: 4 months (Phase 2 portion of study)

  13. Kaplan Meier Estimates of Overall Survival (OS) for Participants in Phase 2

    Overall survival is defined as the time from date of first administration of study interventions until date of death, plus one day. For summary purposes, results are presented as weeks.

    Time frame: Up to 2 years (Phase 2 portion of study)

07

Results

Posted Jun 30, 2011

Participant flow

Phase 1
Participant flow — Phase 1
MilestoneClofarabine, Etoposide, Cyclophosphamide
Started25
Completed0
Not completed25
Withdrew: Refused further treatment1
Withdrew: Failure to achieve response8
Withdrew: Disease relapse4
Withdrew: Scheduled for transplant9
Withdrew: Death3
Phase 2
Participant flow — Phase 2
MilestoneClofarabine, Etoposide, Cyclophosphamide
Started25
Completed0
Not completed25
Withdrew: Physician decision4
Withdrew: Adverse event1
Withdrew: Failure to achieve response3
Withdrew: Disease relapse1
Withdrew: Scheduled for transplant8
Withdrew: Other1
Withdrew: Death7

Outcome measures

PrimaryMaximum Tolerated Dose (MTD) in Phase 1

The MTD was to be the highest dose level of clofarabine in combination with etoposide and cyclophosphamide that caused \<= 1 of 6 participants to experience a dose limiting toxicity (DLT) with the next higher dose level having at least 2 of 3 or 2 of 6 participants experiencing a DLT. The MTD would be used as the recommended phase 2 dose (RP2D). If the MTD could not be determined, then the target dose of clofarabine 40 mg/m\^2, etoposide 100 mg/m\^2 and cyclophosphamide 440 mg/m\^2 as taken by Cohort 5 was to become the RP2D. The rating scale used is 0 = not the MTD, 1 = the MTD.

Time frame:
Up to Day 42 (Phase 1 portion of study)
Reported as:
Number · units on a scale
Maximum Tolerated Dose (MTD) in Phase 1
units on a scalePhase 1 - Cohort 1Phase 1 - Cohort 2Phase 1 - Cohort 3Phase 1 - Cohort 4Phase 1 - Cohort 5
Maximum Tolerated Dose (MTD) in Phase 100000
PrimaryParticipants With Dose Limiting Toxicity in Phase 1

The number of participants in each cohort that had dose limiting toxicity is summarized. Toxicities were reviewed by an independent Data Safety Monitoring Board (DSMB) who determined if additional participants should be added to the cohort and the criteria for escalating to the next cohort.

Time frame:
Up to Day 42 (Phase 1 portion of study)
Reported as:
Number · participants
Participants With Dose Limiting Toxicity in Phase 1
participantsPhase 1 - Cohort 1Phase 1 - Cohort 2Phase 1 - Cohort 3Phase 1 - Cohort 4Phase 1 - Cohort 5
Participants With Dose Limiting Toxicity in Phase 100011
SecondarySummary of Participants With Adverse Events (AEs) in Phase 1

Number of participants with AEs that occurred during treatment and follow-up period (45 days after last cycle). Drug-related AEs and SAEs were followed until resolved or mutually agreed by the investigator and Genzyme to discontinue reporting. AEs were classified by the investigator according to severity (graded using National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE\] version 3.0) and relationship to study drug. The severity scale is:\> Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening or disabling, Grade 5=Death related to AE

Time frame:
Up to 9.5 months (Phase 1 portion of study)
Reported as:
Number · participants
Summary of Participants With Adverse Events (AEs) in Phase 1
participantsPhase 1 - Cohort 1Phase 1 - Cohort 2Phase 1 - Cohort 3Phase 1 - Cohort 4Phase 1 - Cohort 5
At least one AE333106
At least one AE related to clofarabine333106
At least one serious AE33396
At least one serious AE related to clofarabine32395
Discontinued study due to AE00000
Died31395
AE with the worst grade of: 100000
AE with the worst grade of: 200000
AE with the worst grade of: 321133
AE with the worst grade of: 411252
AE with the worst grade of: 501021
SecondaryPercentage of Participants Achieving A Response Over the First Two Treatment Cycles in Phase 1

Response categories 1) complete remission (CR): without circulating blasts or extramedullary disease, bone marrow (BM) with \<5% blasts, and platelet (plt)/ANC recovery: ALL ≥75/ ≥0.75 \[x 10\^9/L\]; AML ≥100/ ≥1.0 \[x 10\^9/L\] 2) CR in absence of plt recovery (CRp): ALL plt ≥20 to \<75 x 10\^9/L; AML plt ≥20 to \<100 x 10\^9/L 3) partial remission (PR): no circulating blasts, appearance of normal hematopoietic progenitors, and either a BM with ≥5% and ≤25% blasts with recovery of plts/ANC or a BM with \<5% blasts not meeting CR/CRp definition 4) Overall remission (OR): CR+CRp 5) Any response: CR+CRp+PR.

Time frame:
Approximately 2 months (Phase 1 portion of study)
Reported as:
Number · percentage of total participants
Percentage of Participants Achieving A Response Over the First Two Treatment Cycles in Phase 1
percentage of total participantsPhase 1: Clofarabine, Etoposide, Cyclophosphamide
Complete remission (CR)40
Complete remission/absence total platelet recovery24
Partial remission (PR)0
Overall remission (OR)64
Any response (CR+CRp+PR)64
SecondaryTime to Remission for Participants Who Had a Response in Phase 1

The weeks between start of intervention and remission as assessed by the investigator in Phase 1. Participants who had a complete remission (CR) or complete remission with the absence of total platelet recovery (CRp) are included.

Time frame:
up to 8 weeks (Phase 1 portion of study)
Reported as:
Mean · weeks
Time to Remission for Participants Who Had a Response in Phase 1
weeksPhase 1: Clofarabine, Etoposide, Cyclophosphamide
Time to Remission for Participants Who Had a Response in Phase 14.96 ± 1.912
SecondaryKaplan Meier Estimate of Duration of Remission (DOR) for Participants Who Achieved Overall Remission (OR) in Phase 1

Duration of response is the time from the first objective measurement of complete response (CR) or complete response with the absence of total platelet recovery (CRp) to the date of first objective documentation of disease relapse or death due to any cause, plus one day. For summary purposes, results are presented as weeks.

Time frame:
Up to 2 years (Phase 1 portion of study)
Reported as:
Median · weeks
Kaplan Meier Estimate of Duration of Remission (DOR) for Participants Who Achieved Overall Remission (OR) in Phase 1
weeksPhase 1: Clofarabine, Etoposide, Cyclophosphamide
Kaplan Meier Estimate of Duration of Remission (DOR) for Participants Who Achieved Overall Remission (OR) in Phase 118.2 (12.9 to 35.0)
SecondaryKaplan Meier Estimates of Event-free Survival (EFS) for Participants in Phase 1

Event-free survival (EFS) is defined as the time from date of first administration of study interventions until the earliest of the following: date of death or date of first response assessment confirming relapse or date of final response assessment which fails to confirm response, plus one day. For summary purposes, results are presented as weeks.

Time frame:
Up to 2 years (Phase 1 portion of study)
Reported as:
Median · weeks
Kaplan Meier Estimates of Event-free Survival (EFS) for Participants in Phase 1
weeksPhase 1: Clofarabine, Etoposide, Cyclophosphamide
Kaplan Meier Estimates of Event-free Survival (EFS) for Participants in Phase 119.3 (12.7 to 27.1)
SecondaryNumber of Participants With 4-month Event Free Survival in Phase 1

Number of participants with event-free survival at four months post first dose of therapy. A participant is considered event-free if at month 4 they have not died or had a response assessment confirming a relapse.

Time frame:
4 months (Phase I portion of study)
Reported as:
Number · participants
Number of Participants With 4-month Event Free Survival in Phase 1
participantsPhase 1: Clofarabine, Etoposide, Cyclophosphamide
Number of Participants With 4-month Event Free Survival in Phase 113
SecondaryKaplan Meier Estimates of Overall Survival (OS) for Participants in Phase 1

Overall survival is defined as the time from date of first administration of study interventions until date of death, plus one day. For summary purposes, results are presented as weeks.

Time frame:
Up to 2 years (Phase 1 portion of study)
Reported as:
Median · weeks
Kaplan Meier Estimates of Overall Survival (OS) for Participants in Phase 1
weeksPhase 1: Clofarabine, Etoposide, Cyclophosphamide
Kaplan Meier Estimates of Overall Survival (OS) for Participants in Phase 127.1 (18.3 to 42.9)
PrimaryPercentage of Participants Achieving A Response Over the First Two Treatment Cycles in Phase 2

Response categories 1) complete remission (CR): without circulating blasts or extramedullary disease, bone marrow (BM) with \<5% blasts, and platelet (plt)/ANC recovery: ≥75/ ≥0.75 \[x 10\^9/L\] 2) CR in absence of plt recovery (CRp): plt ≥20 to \<75 x 10\^9/L 3) partial remission (PR): no circulating blasts, appearance of normal hematopoietic progenitors, and either a BM with ≥5% and ≤25% blasts with recovery of plts/ANC or a BM with \<5% blasts not meeting CR/CRp definition 4) Overall remission (OR): CR+CRp 5) Any response: CR+CRp+PR.

Time frame:
Approximately 28-56 days (Phase 2 portion of study)
Reported as:
Number · percentage of total participants
Percentage of Participants Achieving A Response Over the First Two Treatment Cycles in Phase 2
percentage of total participantsPhase 2: Clofarabine, Etoposide, Cyclophosphamide
Complete remission (CR)28
Complete remission/absence total platelet recovery16
Partial remission (PR)12
Overall remission (OR)44
Any response (CR+CRp+PR)56
SecondarySummary of Participants With Adverse Events (AEs) in Phase 2

Number of participants with AEs that occurred during treatment and follow-up period (45 days after last cycle). Drug-related AEs and SAEs were followed until resolved or mutually agreed by the investigator and Genzyme to discontinue reporting. AEs were classified by the investigator according to severity (graded using National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE\] version 3.0) and relationship to study drug. The severity scale is:\> Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening or disabling, Grade 5=Death related to AE

Time frame:
Up to 9.5 months (Phase 2 portion of study)
Reported as:
Number · participants
Summary of Participants With Adverse Events (AEs) in Phase 2
participantsPhase 2: Clofarabine, Etoposide, Cyclophosphamide
At least one AE25
At least one AE related to clofarabine25
At least one serious AE21
At least one serious AE related to clofarabine20
Discontinued study due to AE1
Died16
AE with the worst grade of: 10
AE with the worst grade of: 20
AE with the worst grade of: 31
AE with the worst grade of: 416
AE with the worst grade of: 58
SecondaryTime to Remission for Participants Who Had a Response in Phase 2

The weeks between start of intervention and remission as assessed by the investigator in Phase 2. Participants who had a complete remission (CR) or complete remission with the absence of total platelet recovery (CRp) are included.

Time frame:
up to 8 weeks (Phase 2 portion of study)
Reported as:
Mean · weeks
Time to Remission for Participants Who Had a Response in Phase 2
weeksPhase 2: Clofarabine, Etoposide, Cyclophosphamide
Time to Remission for Participants Who Had a Response in Phase 24.84 ± 2.092
SecondaryKaplan Meier Estimate of Duration of Remission (DOR) for Participants Who Achieved Overall Remission (OR) in Phase 2

Duration of response is the time from the first objective measurement of complete response (CR) or complete response with the absence of total platelet recovery (CRp) to the date of first objective documentation of disease relapse or death due to any cause, plus one day. For summary purposes, results are presented as weeks.

Time frame:
Up to 2 years (Phase 2 portion of study)
Reported as:
Median · weeks
Kaplan Meier Estimate of Duration of Remission (DOR) for Participants Who Achieved Overall Remission (OR) in Phase 2
weeksPhase 2: Clofarabine, Etoposide, Cyclophosphamide
Kaplan Meier Estimate of Duration of Remission (DOR) for Participants Who Achieved Overall Remission (OR) in Phase 267.3 (13.4 to NA)
SecondaryKaplan Meier Estimates of Event-free Survival (EFS) for Participants in Phase 2

Event-free survival (EFS) is defined as the time from date of first administration of study interventions until the earliest of the following: date of death or date of first response assessment confirming relapse or date of final response assessment which fails to confirm response, plus one day. For summary purposes, results are presented as weeks.

Time frame:
Up to 2 years (Phase 2 portion of study)
Reported as:
Median · weeks
Kaplan Meier Estimates of Event-free Survival (EFS) for Participants in Phase 2
weeksPhase 2: Clofarabine, Etoposide, Cyclophosphamide
Kaplan Meier Estimates of Event-free Survival (EFS) for Participants in Phase 210.7 (6.7 to 73.9)
SecondaryNumber of Participants With 4-month Event Free Survival in Phase 2

Number of participants with event-free survival at four months post first dose of therapy. A participant is considered event-free if at month 4 they have not died or had a response assessment confirming a relapse.

Time frame:
4 months (Phase 2 portion of study)
Reported as:
Number · participants
Number of Participants With 4-month Event Free Survival in Phase 2
participantsPhase 2: Clofarabine, Etoposide, Cyclophosphamide
Number of Participants With 4-month Event Free Survival in Phase 211
SecondaryKaplan Meier Estimates of Overall Survival (OS) for Participants in Phase 2

Overall survival is defined as the time from date of first administration of study interventions until date of death, plus one day. For summary purposes, results are presented as weeks.

Time frame:
Up to 2 years (Phase 2 portion of study)
Reported as:
Median · weeks
Kaplan Meier Estimates of Overall Survival (OS) for Participants in Phase 2
weeksPhase 2: Clofarabine, Etoposide, Cyclophosphamide
Kaplan Meier Estimates of Overall Survival (OS) for Participants in Phase 210.7 (8.1 to 38.6)

Adverse events

Collected over Treatment emergent adverse experiences collected in Phase 1 from day 1 up to 9.5 months. Phase 2 also lasted up to 9.5 months and started after Phase 1.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1 - Cohort 1—3/3 (100%)3/3 (100%)
Phase 1 - Cohort 2—3/3 (100%)3/3 (100%)
Phase 1 - Cohort 3—3/3 (100%)3/3 (100%)
Phase 1 - Cohort 4—9/10 (90%)10/10 (100%)
Phase 1 - Cohort 5—6/6 (100%)6/6 (100%)
Phase 1 - Total—24/25 (96%)25/25 (100%)
Phase 2: Clofarabine, Etoposide, Cyclophosphamide—21/25 (84%)25/25 (100%)
Most frequent serious events
Showing 10 of 116
Most frequent serious events
EventPhase 1 - Cohort 1Phase 1 - Cohort 2Phase 1 - Cohort 3Phase 1 - Cohort 4Phase 1 - Cohort 5Phase 1 - TotalPhase 2: Clofarabine, Etoposide, Cyclophosphamide
Febrile neutropeniaBlood and lymphatic system disorders3/31/33/37/103/617/2515/25
PyrexiaGeneral disorders1/30/33/32/100/66/253/25
NeutropeniaBlood and lymphatic system disorders1/30/31/31/102/65/250/25
TrichiasisEye disorders0/30/31/30/100/61/250/25
Abdominal painGastrointestinal disorders0/31/30/31/100/62/251/25
AscitesGastrointestinal disorders0/31/30/30/100/61/250/25
CaecitisGastrointestinal disorders0/30/31/33/100/64/253/25
Rectal fissureGastrointestinal disorders0/30/31/30/100/61/250/25
Generalised oedemaGeneral disorders0/31/30/30/100/61/250/25
Drug hypersensitivityImmune system disorders0/31/30/30/100/61/250/25
Most frequent other events
Showing 10 of 335
Most frequent other events
EventPhase 1 - Cohort 1Phase 1 - Cohort 2Phase 1 - Cohort 3Phase 1 - Cohort 4Phase 1 - Cohort 5Phase 1 - TotalPhase 2: Clofarabine, Etoposide, Cyclophosphamide
NauseaGastrointestinal disorders2/32/33/39/105/621/2520/25
VomitingGastrointestinal disorders2/32/33/39/106/622/2522/25
EpistaxisRespiratory, thoracic and mediastinal disorders0/30/33/33/101/67/254/25
Abdominal painGastrointestinal disorders1/30/31/39/102/613/257/25
DiarrhoeaGastrointestinal disorders2/32/31/37/105/617/257/25
PyrexiaGeneral disorders2/30/31/37/105/615/2513/25
HeadacheNervous system disorders1/30/32/37/104/614/259/25
AnaemiaBlood and lymphatic system disorders1/31/32/31/102/67/2516/25
ThrombocytopeniaBlood and lymphatic system disorders1/30/32/35/103/611/2516/25
Ear painEar and labyrinth disorders0/30/32/31/101/64/250/25

Baseline characteristics

Age, Continuous
Age, Continuous(years)Phase 1: Clofarabine, Etoposide, CyclophosphamidePhase 2: Clofarabine, Etoposide, CyclophosphamideTotal
Mean9.1 ± 5.0313.2 ± 5.2511.2 ± 5.49
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1: Clofarabine, Etoposide, CyclophosphamidePhase 2: Clofarabine, Etoposide, CyclophosphamideTotal
Female10919
Male151631
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1: Clofarabine, Etoposide, CyclophosphamidePhase 2: Clofarabine, Etoposide, CyclophosphamideTotal
Hispanic or Latino51015
Not Hispanic or Latino201535
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1: Clofarabine, Etoposide, CyclophosphamidePhase 2: Clofarabine, Etoposide, CyclophosphamideTotal
American Indian or Alaska Native011
Asian325
Native Hawaiian or Other Pacific Islander000
Black or African American426
White161228
More than one race000
Unknown or Not Reported2810
Percent Leukemic Blast Cells
Percent Leukemic Blast Cells(percentage of total blast cells)Phase 1: Clofarabine, Etoposide, CyclophosphamidePhase 2: Clofarabine, Etoposide, CyclophosphamideTotal
Mean66.8 ± 24.8569.52 ± 23.56668.16 ± 24.008
Absolute Neutrophil Counts
Absolute Neutrophil Counts(10^9/L)Phase 1: Clofarabine, Etoposide, CyclophosphamidePhase 2: Clofarabine, Etoposide, CyclophosphamideTotal
Mean1.93828 ± 3.0499921.9280 ± 1.7081261.93325 ± 2.459536
White Blood Cell Counts
White Blood Cell Counts(10^9/L)Phase 1: Clofarabine, Etoposide, CyclophosphamidePhase 2: Clofarabine, Etoposide, CyclophosphamideTotal
Mean8.323 ± 9.130512.171 ± 23.015010.247 ± 17.4370
Immunophenotype
Immunophenotype(participants)Phase 1: Clofarabine, Etoposide, CyclophosphamidePhase 2: Clofarabine, Etoposide, CyclophosphamideTotal
B cell132134
T cell516
Unknown235
not included (AML participants)505

4 further baseline measures are reported on the registry.

08

Study locations

13 sites
  • Children's Hospital of Alabama
    Birmingham, Alabama, United States
  • Children's Hospital of Los Angeles
    Los Angeles, California, United States
  • Rady Children's Hospital
    San Diego, California, United States
  • Connecticut Children's Medical Center
    Hartford, Connecticut, United States
  • Children's Memorial Hospital
    Chicago, Illinois, United States
  • St. Vincent Children's Hospital
    Indianapolis, Indiana, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts, United States
  • Children's Hospital of Michigan
    Detroit, Michigan, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York, United States
  • New York School of Medicine
    New York, New York, United States
  • St. Jude Children's Research Hospital
    Memphis, Tennessee, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas, United States
  • Seattle Children's Hospital
    Seattle, Washington, United States
09

References and documents

Publications

  • Hijiya N, Thomson B, Isakoff MS, Silverman LB, Steinherz PG, Borowitz MJ, Kadota R, Cooper T, Shen V, Dahl G, Thottassery JV, Jeha S, Maloney K, Paul JA, Barry E, Carroll WL, Gaynon PS. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood. 2011 Dec 1;118(23):6043-9. doi: 10.1182/blood-2011-08-374710. Epub 2011 Oct 3. PubMed 21967976 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2006, a primary completion of May 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2006
First posted
Apr 19, 2006
Start
Mar 2006
Primary completionActual
May 2010
CompletionActual
May 2010
Results first posted
Jun 30, 2011
Last update
Apr 14, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00315705
Responsible party
Sponsor
First posted
Apr 19, 2006
Start date
Mar 2006
Primary completion
May 2010
Completion
May 2010
Results posted
Jun 30, 2011
Last update
Apr 14, 2014

Study contacts

Medical Monitor
study director · Genzyme, a Sanofi Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Clofarabine · Etoposide · Cyclophosphamide

Start the discussion